Cornerstone Advisors (Washington)’s Pliant Therapeutics PLRX Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1K	Buy	+42	New	+$1.05K	﹤0.01%	681

Other funds holding PLRX

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Cornerstone Advisors (Washington)'s PLRX Position: Q3 2020 in Review

Cornerstone Advisors (Washington) opened a new position in Pliant Therapeutics (PLRX) in Q3 2020: 42 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #681 among its holdings.

55 funds tracked by Wall St. Rank hold PLRX as of Q3 2020.

Cornerstone Advisors (Washington) held 42 shares of Pliant Therapeutics worth $1K as of Q3 2020.
Pliant Therapeutics was a new Cornerstone Advisors (Washington) position in Q3 2020.
Pliant Therapeutics made up ﹤0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #681 holding.
55 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.